Eligibility for Country of Origin Claims in the Complementary Medicines Sector – RIS Consultation

For background see: https://www.medreach.com.au/made-in-australia-complementary-medicine-taskforce-established-foi-report-outcome/

For the Regulatory Impact Statement Consultation Report. Eligibility for Country of Origin claims in the Complementary Medicines Sector. Department of Industry, Innovation and Science. See: https://consult.industry.gov.au/cool-taskforce/clarifying-eligibility-for-origin-claims/supporting_documents/EligibilityfororiginclaimsintheComplementaryMedicineSectorRIS.PDF

The options suggested:

I support option 3c.

Pros:

  • Consumers would benefit from an easily identifiable visual representation of the proportion of imported ingredients.
  • Consumers would be informed of the proportion of ingredients that are imported.
  • Consumers are already familiar with the combination of AMAG logo and ingredient proportion bar chart from food labelling, so replicating that style on complementary medicines would require little adjustment from consumers.

Cons:

  • Manufactures may not want to provide information on the label that ingredients are imported.
  • More information on the label may be a cost to manufacturers.
  • Cost to manufacturers to track proportion of imported ingredients and adjust labelling as required.
  • Manufacturers may see the bar charts a detriment to their marketing efforts.

Conclusion:

Benefits to consumers should be prioritised over minor problems to manufacturers.

linkedinrsslinkedinrssby feather

About Dr Ken Harvey

Public Health Physician, Medical activitist
This entry was posted in Complementary medicine, Pharmaceutical Promotion and tagged , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.